# SYNTAXISBIO MATERIAL TRANSFER AGREEMENT

**IMPORTANT LEGAL NOTICE: This is a template document for review and customization by qualified legal counsel. Do not use without attorney review and modification for your specific business needs and jurisdiction.**

---

## MATERIAL TRANSFER AGREEMENT

This Material Transfer Agreement ("MTA") is entered into as of \_\_\_\_\_\_\_\_\_\_ ("Effective Date") by and between:

**SyntaxisBio** ("Provider")
[Address]
[City, State ZIP]
Email: info@syntaxisbio.com

and

**[Recipient Name]** ("Recipient")
[Institution/Organization]
[Address]
[City, State ZIP]
Email: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Principal Investigator (if applicable):**
Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Title: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Email: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

---

## 1. MATERIAL DESCRIPTION

1.1 **Material Being Transferred.**

[ ] **FROM Recipient TO Provider** (for cell line engineering services)
- Cell Line Name/Description: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
- Source/Catalog Number: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
- Passage Number: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
- Biosafety Level: BSL-\_\_\_\_
- Quantity: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
- Additional Materials (plasmids, donor templates, etc.): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

[ ] **FROM Provider TO Recipient** (delivery of engineered cell lines)
- Cell Line Name/Description: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
- Genetic Modifications: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
- Passage Number: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
- Biosafety Level: BSL-\_\_\_\_
- Quantity: \_\_\_\_ vials, \_\_\_\_\_\_ cells per vial
- PUF Authentication: [ ] Yes [ ] No
- Service Order Reference: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1.2 **Accompanying Documentation.** Material shall be accompanied by:
- Certificate of Analysis (if applicable)
- Safety Data Sheet or Biosafety information
- Culture and handling protocols
- Sequence verification data (for engineered lines)

---

## 2. RECIPIENT'S REPRESENTATIONS AND WARRANTIES

Recipient represents and warrants that:

2.1 **Rights to Material.** For material being transferred TO Provider: Recipient has full legal right and authority to provide the material to Provider and has obtained all necessary permissions and approvals.

2.2 **Institutional Approval.** Recipient's institution has reviewed and approved this transfer and the associated research activities under all applicable institutional policies, including but not limited to:
   - Institutional Biosafety Committee (IBC) approval
   - Institutional Review Board (IRB) approval (if human subjects research)
   - Animal Care and Use Committee (IACUC) approval (if applicable)
   - Technology transfer or material transfer office approval

2.3 **Accurate Information.** All information provided about the material, including biosafety level, origin, and characteristics, is accurate and complete to the best of Recipient's knowledge.

2.4 **No Third-Party Restrictions.** The material is not subject to any third-party restrictions that would prohibit or limit this transfer, OR Recipient has obtained necessary consents and shall provide documentation.

2.5 **Indemnification for Misrepresentation.** Recipient shall indemnify and hold harmless Provider from any claims, damages, or expenses arising from breach of these warranties, including but not limited to third-party intellectual property infringement claims.

---

## 3. PERMITTED USE

3.1 **Research Use Only.** Material is provided solely for non-commercial research purposes unless otherwise agreed in writing. Material shall not be used for:
   - Clinical diagnostic purposes
   - Human therapeutic purposes
   - Commercial product development without separate written agreement

3.2 **Location of Use.** Material shall be used only at Recipient's institution at the address stated above, unless Provider provides prior written consent for use at other locations.

3.3 **Trained Personnel.** Material shall be handled only by qualified personnel trained in appropriate biosafety and laboratory techniques.

---

## 4. RESTRICTIONS ON MATERIAL USE

4.1 **No Distribution.** Recipient shall NOT distribute, transfer, or share the Material with any third party without Provider's prior written consent.

4.2 **No Reverse Engineering.** For material transferred FROM Provider TO Recipient: Recipient shall not attempt to reverse engineer, sequence, or analyze Provider's proprietary PUF authentication technology or methodologies.

4.3 **No Commercial Use.** Recipient shall not use Material for commercial purposes, including but not limited to:
   - Sale or distribution of Material
   - Screening or developing commercial products
   - Providing services to third parties

   without executing a separate commercial license agreement with Provider.

4.4 **No Modifications for Transfer.** Recipient may make modifications to Material for Recipient's own research but shall not distribute modified Material without Provider's written consent.

---

## 5. INTELLECTUAL PROPERTY

5.1 **Provider Retains Ownership.** Provider retains all ownership rights to the Material. This MTA does not grant Recipient any intellectual property rights, licenses, or interests except as expressly stated herein.

5.2 **Recipient's Discoveries.** Intellectual property rights to Recipient's discoveries made through use of the Material shall be determined as follows:
   - Discoveries based solely on Recipient's research: owned by Recipient
   - Discoveries incorporating Provider's proprietary technology: subject to Provider's retained rights
   - Joint discoveries: subject to good faith negotiation of rights

5.3 **PUF Technology Rights.** All rights to genetic PUF authentication technology, including methods, algorithms, and implementations, remain the exclusive property of Provider. No rights are granted to Recipient to practice, use, or commercialize this technology outside of the specific Material provided.

5.4 **Publication Rights.** Recipient may publish research results obtained using Material, subject to the following conditions:
   - Recipient shall provide Provider with draft manuscript 30 days prior to submission
   - Provider may request removal of confidential information about Provider's proprietary methods
   - Provider may request delay of publication for up to 60 days to file patent applications
   - Recipient shall acknowledge Provider as follows: "Engineered cell lines were provided by SyntaxisBio"

---

## 6. WARRANTIES AND DISCLAIMERS

6.1 **Material Provided "AS IS."** MATERIAL IS PROVIDED "AS IS" WITHOUT ANY WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

6.2 **No Warranty of Viability.** Provider does not warrant that Material will be viable, free from contamination (except mycoplasma at time of shipment), or suitable for Recipient's intended purposes.

6.3 **Shipping Conditions.** Material condition may be affected by shipping and handling. Provider is not responsible for viability loss during shipping.

6.4 **Recipient Assumes Risk.** Recipient assumes all risk and liability for receipt, storage, handling, and use of Material.

---

## 7. BIOSAFETY AND COMPLIANCE

7.1 **Biosafety Compliance.** Recipient shall:
   - Handle Material in accordance with applicable biosafety regulations
   - Maintain appropriate containment as specified by institutional biosafety committee
   - Train all personnel handling Material in appropriate safety procedures
   - Report any safety incidents to Provider within 24 hours

7.2 **Regulatory Compliance.** Recipient shall comply with all applicable laws, regulations, and institutional policies, including but not limited to:
   - NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules
   - CDC and USDA Select Agent Regulations (if applicable)
   - State and local regulations governing biological materials
   - Export control regulations

7.3 **Disposal.** Recipient shall dispose of Material in accordance with applicable regulations and institutional procedures for biological waste.

---

## 8. LIABILITY AND INDEMNIFICATION

8.1 **LIMITED LIABILITY.** TO THE MAXIMUM EXTENT PERMITTED BY LAW, PROVIDER'S LIABILITY ARISING OUT OF OR RELATED TO THIS MTA SHALL NOT EXCEED $500. PROVIDER SHALL NOT BE LIABLE FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, OR PUNITIVE DAMAGES.

8.2 **Recipient Indemnification.** Recipient shall indemnify, defend, and hold harmless Provider, its officers, employees, and agents from and against any and all claims, damages, losses, liabilities, and expenses (including reasonable attorneys' fees) arising from:
   - Recipient's receipt, storage, handling, or use of Material
   - Recipient's breach of this MTA
   - Any injury, illness, or damage caused by Material at Recipient's facility or through Recipient's actions
   - Third-party claims related to Recipient's use of Material

---

## 9. CONFIDENTIALITY

9.1 **Confidential Information.** Each party agrees to maintain in confidence any proprietary information disclosed by the other Party in connection with this MTA.

9.2 **Provider Proprietary Information.** Recipient acknowledges that information about Provider's PUF authentication technology, methodologies, and processes constitutes Provider's confidential and proprietary information.

9.3 **Term.** Confidentiality obligations shall survive for 5 years after termination of this MTA.

---

## 10. TERM AND TERMINATION

10.1 **Term.** This MTA shall commence on the Effective Date and continue until:
   - Completion of the research project (estimated date: \_\_\_\_\_\_\_\_\_\_)
   - Termination by either Party with 30 days written notice
   - 2 years from Effective Date, whichever occurs first

10.2 **Extension.** This MTA may be extended by written agreement of both Parties.

10.3 **Termination Obligations.** Upon termination, Recipient shall:
   - Cease all use of Material
   - Destroy or return all Material and derivatives to Provider (at Provider's election)
   - Provide written certification of destruction or return within 30 days
   - Continue to maintain confidentiality obligations

10.4 **Survival.** Sections 2.5 (Indemnification), 5 (Intellectual Property), 6 (Warranties), 8 (Liability), and 9 (Confidentiality) shall survive termination.

---

## 11. EXPORT CONTROL

11.1 **Export Compliance.** Recipient shall comply with all applicable U.S. export control laws and regulations, including but not limited to the Export Administration Regulations (EAR) and International Traffic in Arms Regulations (ITAR).

11.2 **No Export Without Authorization.** Recipient shall not export, re-export, or transfer Material or related technical data to any foreign country or foreign person without obtaining necessary authorizations from the U.S. Government.

11.3 **Recipient Represents.** Recipient represents that Recipient and its personnel are not located in, under control of, or a national or resident of any U.S.-embargoed country or on any U.S. government prohibited parties list.

---

## 12. GENERAL PROVISIONS

12.1 **Entire Agreement.** This MTA constitutes the entire agreement between the Parties regarding the Material and supersedes all prior agreements and understandings.

12.2 **Amendments.** This MTA may be amended only by written agreement signed by authorized representatives of both Parties.

12.3 **Governing Law.** This MTA shall be governed by the laws of [State], without regard to conflicts of law principles.

12.4 **Dispute Resolution.** Disputes shall be resolved through good faith negotiation, followed by mediation in [City, State] if necessary.

12.5 **Severability.** If any provision is found invalid or unenforceable, the remaining provisions shall remain in full force and effect.

12.6 **Assignment.** Recipient may not assign this MTA without Provider's prior written consent.

12.7 **Notices.** All notices shall be in writing and sent to the addresses stated above.

---

## 13. SHIPPING INFORMATION

**Ship Material TO:**
[ ] Provider Address: SyntaxisBio, [Full Shipping Address]
[ ] Recipient Address: [Full Shipping Address]

**Shipping Method:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
**Tracking Number:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
**Expected Delivery Date:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

---

## SIGNATURES

Both Parties acknowledge that they have read, understood, and agree to be bound by all terms and conditions of this Material Transfer Agreement.

**PROVIDER: SyntaxisBio**

By: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Title: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**RECIPIENT: [Recipient Name/Institution]**

By: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Title: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Authorized Institutional Representative (if required):**

By: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Title: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

---

**LEGAL DISCLAIMER:** This template is provided for informational purposes only and does not constitute legal advice. Before using this agreement, you must have it reviewed and customized by a licensed attorney familiar with your business, jurisdiction, and specific circumstances. Laws vary by state and country, and this template may not address all legal requirements or protect all of your interests.
